Resonance Specialties net profit rises 58% to ₹10.40 crore in FY26

1 min read     Updated on 09 Jul 2026, 10:57 AM
scanx
Reviewed by
Shriram SScanX News Team
AI Summary

Resonance Specialities Limited reported a 58% rise in net profit to ₹10.40 crore for FY26, with total income increasing 17% to ₹91.89 crore. The board recommended a dividend of ₹1 per share and approved the re-appointment of statutory auditors.

powered bylight_fuzz_icon
45120432

*this image is generated using AI for illustrative purposes only.

Resonance Specialities Limited reported a net profit of ₹10.40 crore for the financial year ended March 31, 2026, a 58% increase from ₹6.57 crore in the previous year. Total income for the period rose 17% to ₹91.89 crore, compared to ₹78.79 crore in FY25, primarily driven by higher sales and export business in key products. The company’s earnings per share (EPS) improved to ₹9.01 from ₹5.69 in the previous year.

Financial Performance

The company’s profit before tax stood at ₹14.07 crore, up from ₹8.88 crore in the previous year. Profit before interest, depreciation, and taxation increased to ₹15.65 crore from ₹11.58 crore. The board has recommended an equity dividend of ₹1 per share (10%) for the financial year, amounting to ₹1.15 crore, which will be paid on or before August 28, 2026, if approved at the Annual General Meeting.

Particulars FY26 (₹ in Lacs) FY25 (₹ in Lacs)
Total Income 9,188.93 7,878.69
Profit Before Tax 1,407.35 887.82
Net Profit 1,039.58 656.62
Earnings Per Share (₹) 9.01 5.69

Operational Highlights

The financial performance improved due to increased sales and export business. The company’s exports, including deemed exports, were recorded at ₹53.55 crore, compared to ₹34.11 crore in the previous year. Resonance Specialities focuses on manufacturing pyridine and pyridine derivatives, picolines, and bulk drugs. The company continues to explore newer markets for its products.

Corporate Governance and Approvals

The board has approved the re-appointment of M/s. Kailash Chand Jain & Co., Chartered Accountants, as statutory auditors for a further period of five years. Additionally, the board has sought shareholder approval to enter into related party transactions with Kaygee Laboratories Private Limited up to a maximum aggregate value of ₹40 crore in any given financial year. The 37th Annual General Meeting is scheduled for August 4, 2026, via video conferencing.

Historical Stock Returns for Resonance Specialties

1 Day5 Days1 Month6 Months1 Year5 Years
+1.31%-4.89%+5.21%+24.07%+11.33%-11.71%

What specific new markets is Resonance Specialities targeting to sustain its export growth momentum?

How will the proposed related party transactions with Kaygee Laboratories impact the company's operational synergy and financial health?

What capital expenditure plans are in place to expand manufacturing capacity for pyridine derivatives and bulk drugs?

like20
dislike

Resonance Specialties fixes record date for Re 1 dividend

1 min read     Updated on 07 Jul 2026, 08:53 PM
scanx
Reviewed by
Anirudha BScanX News Team
AI Summary

Resonance Specialties Limited has fixed July 28, 2026 as the record date for a Re 1 per share dividend, pending approval at its 37th AGM on August 4, 2026. The dividend, representing 10% of the face value, will be paid on or before August 28, 2026. The AGM will be held via video conferencing, with e-voting facilities available from July 31 to August 3, 2026.

powered bylight_fuzz_icon
44449989

*this image is generated using AI for illustrative purposes only.

Resonance Specialties Limited has fixed Tuesday, July 28, 2026 as the record date to determine member eligibility for a dividend of Re 1 per share. The dividend, equivalent to 10% of the face value of Rs 10 each, is subject to approval at the company's ensuing 37th Annual General Meeting (AGM). If sanctioned, the payout will be made on or before August 28, 2026.

The company's 37th AGM is scheduled for Tuesday, August 4, 2026, at 12:30 p.m. via video conferencing. The meeting will be conducted in compliance with the Companies Act, 2013, and SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. Members attending through video conferencing will be reckoned for the purpose of quorum under Section 103 of the Act.

The Notice of the AGM and the Financial Statements for the Financial Year 2025-26, along with the Board of Directors' and Auditors' reports, will be sent exclusively by email to members whose email addresses are registered with the company, the Registrar and Share Transfer Agent (RTA), or Depository Participants. These documents will also be available on the company's website, the BSE Limited website, and the National Securities Depository Limited (NSDL) website.

Meeting Detail Information
Event 37th Annual General Meeting
Date August 4, 2026
Time 12:30 p.m.
Mode Video Conferencing / Other Audio Visual Means
Financial Year 2025-26
Record Date July 28, 2026
Dividend Re 1 per share (10%)
Payment Date On or before August 28, 2026

The company has provided an electronic voting facility for members to exercise their rights on the agenda items. E-voting services will be provided by NSDL, and members can also vote during the AGM. Members holding shares in physical mode must send an email to the company or the RTA with their registered Folio Number, email address, self-attested PAN card, address proof, contact number, and bank account details to receive annual reports and dividends.

Historical Stock Returns for Resonance Specialties

1 Day5 Days1 Month6 Months1 Year5 Years
+1.31%-4.89%+5.21%+24.07%+11.33%-11.71%

How will the proposed dividend impact Resonance Specialties' cash flow and future capital allocation plans?

What strategic initiatives or growth targets does the company plan to outline during the 37th AGM?

How might the shift to digital-only distribution of financial statements affect shareholder engagement and transparency?

like16
dislike

More News on Resonance Specialties

Must Read Next

Earnings

Corporate Actions

Stocks

1 Year Returns:+11.33%